Atea Pharmaceuticals Announces Promising New Data for Bemnifosbuvir and Ruzasvir Combination in Hepatitis C Treatment at The Liver Meeting® 2025

Atea Pharmaceuticals Inc. has announced that new data supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV) infection will be presented at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD). The presentations will include results from a Phase 2 study evaluating the combination's multi-scale HCV modeling outcomes and viral resistance analysis, as well as findings from a Phase 1 study on the potential food effect with the fixed-dose combination. The abstracts will be available on the AASLD website following the embargo lift on October 7, 2025, and the meeting will take place November 7-11, 2025, in Washington, DC. Following the event, Atea will host a virtual investor meeting featuring hepatology and HCV experts to discuss the current treatment landscape and the ongoing global Phase 3 clinical development of the regimen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541009-en) on October 07, 2025, and is solely responsible for the information contained therein.